Summary
It is important to understand the temporal trend of pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load to estimate the transmission potential of children in schools and communities. We determined differences in SARS-CoV-2 viral load dynamics between nasopharyngeal samples of infected asymptomatic and symptomatic children. The daily cycle threshold values of SARS-CoV-2 in the nasopharynx of a cohort of infected children were collected for analysis. Among 17 infected children, 10 (58.8%) were symptomatic. Symptomatic children, when compared to asymptomatic children, had higher viral load (mean cycle threshold on day 7 of illness 28.6 versus 36.7, p = 0.02). Peak SARS-CoV-2 viral loads occured around days 2-3 of illness/days of diagnosis in infected children. After adjusting for the estimated date of infection, the higher SARS-CoV-2 viral loads in symptomatic children remained. We postulate that symptomatic SARS-CoV-2-infected children may have higher transmissibility than asymptomatic children. As peak viral load in infected children occurred in the early stage of illness, viral shedding and transmission in the pre-symptomatic phase probable. Our study highlights the importance of screening for SARS-CoV-2 in children with epidemiological risk factors, even when they are asymptomatic in order to improve containment of the virus in the community, including educational settings.
Key points
Symptomatic children had higher SARS-CoV-2 viral loads in the nasopharynx than asymptomatic children, which may indicate that symptomatic children have higher transmissibility.
Peak SARS-CoV-2 viral loads occurred early around 2-3 days post symptom onset iin children and therefore, pre-symptomatic transmission of the virus is probable.
Symptom based screening for SARS-CoV-2 may not be effective in diagnosing coronavirus disease 2019 (COVID-19) in children as a proportion of children may be asymptomatic or pauci-symptomatic.
Children with high epidemiological risk factors should be screened or isolated as they may be carriers of the virus and contribute to transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not receive funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional ethics review board. Written informed consent was waived in light of the need to inform public health outbreak control policies.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The readers can contact the corresponding author if they want access to the resources and data necessary to replicate the findings discussed in this paper.
